- Home
- BPYPO vs TGTX Comparison
BPYPO vs TGTX Comparison
Compare BPYPO & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BPYPO
- TGTX
- Stock Information
- Founded
- BPYPO N/A
- TGTX 1993
- Country
- BPYPO Bermuda
- TGTX United States
- Employees
- BPYPO 30200
- TGTX N/A
- Industry
- BPYPO Real Estate
- TGTX Biotechnology: Pharmaceutical Preparations
- Sector
- BPYPO Finance
- TGTX Health Care
- Exchange
- BPYPO Nasdaq
- TGTX Nasdaq
- Market Cap
- BPYPO N/A
- TGTX 4.2B
- IPO Year
- BPYPO N/A
- TGTX 1995
- Fundamental
- Price
- BPYPO $14.88
- TGTX $31.75
- Analyst Decision
- BPYPO
- TGTX Strong Buy
- Analyst Count
- BPYPO 0
- TGTX 4
- Target Price
- BPYPO N/A
- TGTX $42.50
- AVG Volume (30 Days)
- BPYPO N/A
- TGTX 2.0M
- Earning Date
- BPYPO N/A
- TGTX 11-03-2025
- Dividend Yield
- BPYPO N/A
- TGTX N/A
- EPS Growth
- BPYPO N/A
- TGTX N/A
- EPS
- BPYPO N/A
- TGTX 0.36
- Revenue
- BPYPO N/A
- TGTX $454,069,000.00
- Revenue This Year
- BPYPO N/A
- TGTX $82.58
- Revenue Next Year
- BPYPO N/A
- TGTX $44.99
- P/E Ratio
- BPYPO N/A
- TGTX $87.91
- Revenue Growth
- BPYPO N/A
- TGTX 30.96
- 52 Week Low
- BPYPO N/A
- TGTX $21.16
- 52 Week High
- BPYPO N/A
- TGTX $46.48
- Technical
- Relative Strength Index (RSI)
- BPYPO 53.45
- TGTX 54.67
- Support Level
- BPYPO $14.65
- TGTX $31.34
- Resistance Level
- BPYPO $14.93
- TGTX $32.56
- Average True Range (ATR)
- BPYPO 0.30
- TGTX 1.09
- MACD
- BPYPO -0.01
- TGTX 0.45
- Stochastic Oscillator
- BPYPO 53.76
- TGTX 68.33
About BPYPO Brookfield Property Partners L.P.
Brookfield Property Partners LP owns, operates, and invests in commercial properties in North America, Europe, Australia, and Brazil. The company focuses on being an owner and operator of real estate, providing investors with diversified exposure to some of the iconic properties and acquiring high-quality assets at a discount to replacement cost or intrinsic value. Its operating segment includes Core Office, Core Retail, LP Investments, and Corporate Segments. The company operates in various sectors such as the office sector, retail sector, industrial, multifamily, hospitality, triple net lease, and corporate sector. It generates a majority of revenue from the LP Investments segment.
About TGTX TG Therapeutics Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.